# WHotLAMP: A simple, inexpensive, and sensitive molecular test for the detection of SARS-CoV-2 in saliva

David Ng[1], Ana Pinharanda[2,†], Merly C. Vogt[2,3,†], Ashok Litwin-Kumar[1], Kyle Stearns[4], Urvashi Thopte[1], Enrico Cannavo[1], Armen Enikolopov, Felix Fiederling[1], Stylianos Kosmidis[1], Barbara Noro[1], Ines Rodrigues-Vaz[1], Hani Shayya[1], Peter Andolfatto[2], Darcy S. Peterka[1], Tanya Tabachnik[1], Jeanine D'Armiento[4,5], Monica Goldklang[4,5], Andres Bendesky[1,6,*]

[1]Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, 10027, USA
[2]Department of Biological Sciences, Columbia University, New York, NY, 10027, USA
[3]Howard Hughes Medical Institute, Columbia University, New York, NY, 10027, USA
[4]Department of Anesthesiology, Columbia University Irving Medical Center, New York, NY, 10032, USA
[5]Center for LAM and Rare Lung Diseases, Columbia University Irving Medical Center, New York, NY, 10032
[6]Department of Ecology, Evolution and Environmental Biology, Columbia University, New York, NY, 10027, USA

† Contributed equally

* Correspondence: a.bendesky@columbia.edu

**Abstract**

Despite the development of effective vaccines against SARS-CoV-2, epidemiological control of the virus is still challenging due to slow vaccine rollouts, incomplete vaccine protection to current and emerging variants, and unwillingness to get vaccinated. Therefore, frequent testing of individuals to identify early SARS-CoV-2 infections, contact-tracing and isolation strategies remain crucial to mitigate viral spread. Here, we describe WHotLAMP, a rapid molecular test to detect SARS-CoV-2 in saliva. WHotLAMP is simple to use, highly sensitive (3.6 viral RNA copies per microliter of saliva) and specific, as well as inexpensive, making it ideal for frequent screening. Moreover, WHotLAMP does not require toxic chemicals or specialized equipment and thus can be performed in point-of-care settings, and may also be adapted for resource-limited environments or home use. While applied here to SARS-CoV-2, WHotLAMP can be modified to detect other pathogens, making it adaptable for other diagnostic assays, including for use in future outbreaks.

52 **Introduction**

53 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus with high
54 transmissibility that causes the Coronavirus Disease of 2019 (COVID-19) (Petersen et al., 2020; C. Wang
55 et al., 2021). Unlike SARS-CoV-1, where infectiousness is mostly restricted to the symptomatic phase
56 (Cheng et al., 2004), ~50% of SARS-CoV-2 transmissions occur 1-2 days before symptom onset or
57 through people who never develop symptoms (Casey et al., 2020; Johansson et al., 2021; Walsh et al.,
58 2020). Thus, screening for symptoms is simply not enough to stop SARS-CoV-2 transmission (Paltiel et
59 al., 2020).

60 Testing, combined with contact tracing and social isolation, along with physical barriers such as face
61 masks and distancing became staple strategies to reduce community spread (Stuart et al., 2021).
62 However, in many countries, viral spread has been difficult to contain. This is partly due to insufficient
63 testing infrastructure, which leads to long delays in both access to testing and in obtaining test results.
64 This lag greatly reduces the effectiveness of contact-tracing and isolation strategies (Larremore et al.,
65 2020; Mina et al., 2021).

66 Despite the development of safe and effective vaccines against SARS-CoV-2, the threat of the virus
67 remains high because of the logistical difficulties of global vaccination, limited supply of vaccine doses,
68 and reluctance to get vaccinated (Wouters et al., 2021). Moreover, the emergence of SARS-CoV-2
69 variants that lower the protection conferred by natural or vaccine-induced immunity, suggests that
70 testing will remain an important tool to reduce viral transmission (Madhi et al., 2021; Muik et al., 2021;
71 Z. Wang et al., 2021). Furthermore, without global vaccination coverage there is potential for future viral
72 outbreaks.

73 Frequent testing using 'rapid' tests has been proposed as an effective strategy to survey the population
74 and identify infectious people (Larremore et al., 2020; Mina et al., 2021), permitting a faster and safer
75 reopening of the economy. A frequent testing strategy is effective if a test is: 1) rapid; 2) inexpensive; 3)
76 simple to use (ideally self-administered for convenience and to minimize health-care resources); 4)
77 sensitive enough to identify most infectious people; and 5) highly specific, so that when prevalence is
78 low, most positives tests are true.

79 Initial tests to detect SARS-CoV-2 infection used deep nasopharyngeal swabs followed by RT-qPCR and
80 were conducted by specially trained personnel (Pondaven-Letourmy et al., 2020; US Food and Drug
81 Administration, 2020d). To increase testing capacity and reduce time to get a test result, point-of-care
82 (POC) and home-based diagnosis using 'rapid' tests were developed to detect viral antigens from
83 shallow nasal swabs (US Food and Drug Administration, 2021). While these tests provide quick results,
84 even the most sensitive of antigen tests can only detect ~20,000 viral RNA copies per microliter (μL)
85 (Corman et al., 2021) and may miss up to 30% of people with the high viral loads associated with
86 infectivity (Baro et al., 2021; Cevik et al., 2021; Corman et al., 2021; Mak et al., 2020; Marc et al., 2021;
87 Marks et al., 2021; Regev-Yochay et al., 2021; Scohy et al., 2020; Singanayagam et al., 2020; Wyllie et al.,
88 2020; Yamayoshi et al., 2020).

Other molecular 'rapid' tests detect viral RNA using an isothermal enzymatic reaction to exponentially amplify fragments of the genome (Ben-Assa et al., 2020; Butler et al., 2020; Joung et al., 2020; Rabe & Cepko, 2020; Wei et al., 2021; Zhang et al., 2020), and some have been approved for emergency use for POC and at home (US Food and Drug Administration, 2020a, 2020c). While this type of rapid test is sensitive, they are expensive and/or require specialized equipment (i.e. are not simple to use). Saliva offers several advantages over nasal and nasopharyngeal swabs for the early detection of SARS-CoV-2 infections: it 1) has a higher viral load than swabs early in an infection (Savela et al., 2021; Teo et al., 2021); 2) is easier than swabs to obtain from children, who are often anxious about the swabbing procedure; 3) requires fewer materials to collect, diminishing waste and reliance on resources that can be scarce. Several protocols to detect SARS-CoV-2 from saliva have been described (US Food and Drug Administration, 2020b; Wyllie et al., 2020). However, these approaches require toxic chemicals or specialized equipment (e.g. centrifuges, pipettes, thermocyclers) which make them impractical for POC, home testing, and other resource-limited environments.

Given these considerations, a fast, economical, easy to use test that is both sensitive, specific, and safe, is still required. To this end, we devised WHotLAMP, a rapid molecular test to detect SARS-CoV-2 viral RNA directly from saliva without the need for specialized equipment, with results obtained in 30 minutes. This test extracts RNA from saliva and uses an isothermal enzymatic reaction to amplify and colorimetrically detect SARS-CoV-2 RNA. WHotLAMP is inexpensive, highly sensitive and specific, making it ideal for frequent screening and detection of infectious individuals to limit the spread of SARS-CoV-2.

## Results and Discussion

### A one-tube saliva test to detect SARS-CoV-2 RNA

To develop a simple procedure to extract SARS-CoV-2 RNA from saliva, we leveraged the nucleic acid binding properties of cellulose paper (e.g. Whatman filter paper (Zou et al., 2017)), and molecular detection of SARS-CoV-2 RNA using Loop-mediated isothermal amplification (LAMP), an enzymatic reaction that exponentially amplifies a target nucleic acid sequence at a constant temperature (Notomi et al., 2000). Inspired by work from Liu et al. (Liu et al., 2011), we sought to develop an inexpensive, sensitive and simplified test that did not require potentially dangerous chemicals, and would be suitable for frequent use at POC and adaptable for home use. We initially tested saliva spiked with naked SARS-CoV-2 control RNA and found that a short exposure of Whatman No. 1 filter paper to saliva, followed by brief washes, could capture sufficient SARS-CoV-2 control RNA to be detected in a LAMP reaction with primers directed against SARS-CoV-2 (**Figure 1A**). Amplification of the target sequence leads to a drop in pH, which is detected with a pH-sensitive dye as a color change from pink (negative) to yellow (positive) (Zhang et al., 2020). We next tested whether we could capture encapsulated SARS-CoV-2 RNA particles that were spiked into saliva, using Whatman paper and an established lysis buffer (Zou et al., 2017). This procedure can detect as few as ~4 SARS-CoV-2 particles per µL of saliva (**Figure 1B**). This level of sensitivity is notable, as it has been determined that 90% of COVID-19 patients carry more than 5 copies of SARS-CoV-2 per µL of saliva (Savela et al., 2021; Wyllie et al., 2020). These findings suggest that a strategy using Whatman paper is a viable approach for isolating RNA from SARS-CoV-2 virions in saliva.




**Figure 1.** Loop-mediated isothermal amplification (LAMP) detection of SARS-CoV-2 RNA captured from saliva using Whatman no. 1 filter. **(A)** Detection of naked SARS-CoV-2 RNA in saliva. Saliva with spike-in SARS-CoV-2 RNA (tubes 1-3), saliva without RNA spike-in (tubes 4-6), SARS-CoV-2 RNA added directly to LAMP reaction (tube 7), no template control (tube 8). **(B)** Detection of encapsulated SARS-CoV-2 RNA particles in saliva (tubes 1-4); saliva with spike-in encapsulated RNase P RNA particles (tube 5); saliva with spike-in encapsulated SARS-CoV-2 RNA particles with no extraction treatment (tube 6), saliva alone with no spike-in (tube 7), and no saliva (tube 8). LAMP reactions used N2+E1 primers for detection of SARS-CoV-2 RNA. Concentrations are in copies per microliter of saliva.

Since the original extraction procedure used guanidine hydrochloride (a toxic protein denaturant), we sought an alternative that avoided toxic chemical components. We developed a saliva extraction procedure using only two components, a non-toxic RNA preservative (RNAlater™), and an endopeptidase, Proteinase K. To minimize handling of Whatman paper, we secured a piece of Whatman paper to the bottom of a 1.7 mL centrifuge tube using a small amount of Kwik-Sil™ silicone adhesive. Notably, Kwik-Sil™ did not interfere with the colorimetric pH indicator in the LAMP reaction mixture, whereas other adhesives we examined caused a color change in negative-control reactions without RNA (**Table 1)**.

147
148 **Table 1: Compatibility of materials with colorimetric LAMP**

| Compound | Color change in LAMP (from pink) |
|---|---|
| Kwik-Sil™ silicone elastomer (World Precision Instruments) | N |
| Clear aquarium silicone (Aqueon) | Y |
| Neutral cure silicone (Dow Corning 737) | Y |
| Ultra-clear polyester plastic sheet (dipstick) | N |
| Glue stick (polyamide, Power Adhesives TEC Bond 7718) | Y |
| Glue stick (acrylic, Infinity Bond) | Y |
| Glue stick (high temperature, Allary) | Y |
| Gorilla glue (original, polyurethane) | Y |
| Crazy Glue (Loctite) | Y |
| Scotch permanent double sided tape | Y |
| Rubber cement (Best-Test paper cement) | Y |

149
150
151
152
153 WHotLAMP can be performed entirely in a single 1.7 mL microfuge tube (**Figure 2A**). In this test, viral
154 RNA is preserved using a non-hazardous RNA stabilizing solution and is extracted by a brief Proteinase K
155 digestion. Heating the sample at 95 $^{o}$C inactivates both Proteinase K and SARS-CoV-2 virions (Batéjat et
156 al., 2021), thereby increasing the biosafety of the sample. It was critical to include a wash step to
157 remove both RNAlater solution and saliva that were soaked up by the filter paper, as well as particulates
158 bound to the filter paper. We designed LAMP primer sets throughout the SARS-CoV-2 genome (see
159 Methods), and focused on the primer set (ZI-1, targeting ORF 1a) with the lowest predicted propensity
160 for primer-dimer formation. To evaluate the specificity of the ZI-1 primers, we tested a panel of 22
161 inactivated respiratory pathogens, including SARS-CoV-1, MERS, H1N1 influenza, and common
162 respiratory coronaviruses. We detected SARS-CoV-2 RNA in samples containing encapsulated SARS-CoV-
163 2 RNA particles, but not in samples containing only the other respiratory pathogens (**Figure 2B-E**),
164 indicating that the primers were specific to SARS-CoV-2.
165
166

167




168 **Figure 2.** Specificity of SARS-CoV-2 LAMP primers. **(A)** Schematic of the WHotLAMP assay. **(B)** LAMP
169 reactions using ZI-1 LAMP primers with $1x10^5$ copies of SARS-CoV-1 DNA (tubes 1-3), MERS DNA (tubes
170 4-6), SARS-CoV-2 RNA (tube 7), and no template control (tube 8). **(C)** and **(D)**, same as **(B)** but with
171 CUFC1 or N2+E1 LAMP primers, respectively. **(E)** Triplicate LAMP reactions with ZI-1 LAMP primers using
172 WHotLAMP detecting different respiratory pathogens (pools 1-5), no respiratory pathogens (- Ctrl), and
173 with inactivated SARS-CoV-2 virions (+CoV-2 Ctrl).

174 **Assay consistency**

175 To determine the consistency of RNA extraction from saliva using WHotLAMP, we designed intron-
176 spanning LAMP primers to detect human RAB7A mRNA, a transcript expressed at high levels in multiple
177 tissues (Eisenberg & Levanon, 2013). RAB7A LAMP primers led to a yellow color change with saliva from
178 healthy donors, but not when RNase A was added after Proteinase K treatment, indicating the
179 amplification originated from RNA and not genomic DNA (**Figure 3A and 3B**). In contrast, the reaction
180 control (RPP30) in the CDC-recommended RT-qPCR test panel for SARS-CoV-2 amplifies both genomic
181 DNA as well as cDNA (Dekker et al., 2020). Further testing of additional saliva samples with RAB7A LAMP
182 led to a yellow color change in 20 of 20 samples, indicating that the RAB7A LAMP primers are an
183 appropriate control for benchmarking successful RNA extractions from saliva.




184

185 **Figure 3.** Detection of RAB7A RNA in saliva. **(A)** LAMP reactions using RAB7A LAMP primers with purified
186 RNA from healthy saliva (tubes 1-3), or purified RNA treated with RNase A (tubes 4-6). **(B)** LAMP
187 reactions using WHotLAMP detecting RAB7A in saliva (tubes 1-3), or with RNase A treatment (tubes 4-6).

188

189

190

191 **Color variation among healthy donor saliva and automated scoring of assay**

192 To devise a quantitative colorimetric threshold from which to differentiate between positive and
193 negative LAMP results, we photographed LAMP assays under controlled illumination using a custom-
194 made portable photobox (**Figure 4A**). A potential concern regarding testing saliva using pH-sensitive
195 dyes, rests in how the variability of pH of saliva samples could influence the specificity of this test (Choi
196 et al., 2017). To examine the colorimetric variability of WHotLAMP, we tested saliva samples from 36
197 healthy volunteers (nasal swab SARS-CoV-2 qPCR negative) (**Figure 4B**). The range of hues of these
198 healthy salivas did not overlap with the range of SARS-CoV-2 positive samples, indicating unambiguous
199 colorimetric classification of results (**Figure 4C-D**).

200 **Limit of detection**

201 We next performed a series of dilutions of a SARS-CoV-2 positive saliva sample to estimate the limit of
202 detection (LoD). Using a saliva sample from an individual with a positive nasal swab Ct (threshold cycle)
203 value of 21, we could detect SARS-CoV-2 using WHotLAMP in 20/20 (100%) of saliva samples diluted
204 1:20,000, and 19/20 (95%) of samples diluted 1:40,000, suggesting a LoD of Ct ~36. To better quantify
205 the LoD of our assay, we purified RNA from this saliva and performed RT-qPCR using CDC 2019 nCoV N1
206 and N2 PCR primers. Through interpolation to a standard curve ($R^2$ = 0.99) using a dilution series of a
207 standard (IDT N-gene), we determined that the LoD of WHotLAMP with ZI-1 primers corresponds to ~3.6
208 viral RNA copies/µL saliva. This LoD matches the 4 viral RNA copies/µL of saliva determined using SARS-
209 CoV-2 RNA spiked into saliva (**Figure 1B**), making it >50x more sensitive than other recent saliva LAMP
210 assays (Yang et al., n.d.).

211 **Specificity and sensitivity**

212 To evaluate the clinical sensitivity of WHotLAMP, we tested saliva from patients who at the same time
213 tested positive for SARS-CoV-2 with a nasal swab qPCR. WHotLAMP with ZI-1 primers detected 36/38
214 (94.7%) positives with a Ct value up to 34 (**Figure 5A**). In contrast, CUFC1 primers (Wei et al., 2021)
215 detected only 25/32 (78.1%) positives, amongst the same cohort of SARS-CoV-2 saliva samples (**Figure**
216 **5B**). Previous reports indicate low success in culturing SARS-CoV-2 from patients with a positive nasal
217 swab at a Ct value >34 (Cevik et al., 2021; La Scola et al., 2020), suggesting that the WHotLAMP assay
218 with ZI-1 primers can detect nearly all individuals that carry viral loads considered to be contagious.
219 Furthermore, while the most accurate antigen tests have a false negative rate of ~20% for samples with
220 a Ct <30 (Baro et al., 2021), WHotLAMP with ZI-1 primers detected 21/21 samples that had Ct <31 in
221 nasal swab RT-qPCR.

222 To evaluate the specificity of WHotLAMP, we tested saliva from asymptomatic individuals who had a
223 negative qPCR result from a nasal swab taken within 24 hours of the saliva collection. Notably, we found
224 no false positives among 40 samples (false-positive rate <1/40; CI=0-0.091) using ZI-1 primers, indicating
225 this primer set offers high specificity (**Figure 5C**), whereas CUFC1 primers detected 2 false positives out
226 of 37 samples (a subset of the 40 tested with ZI-1; false-positive rate 0.054; CI=0.0097-0.18) (**Figure 5D**).

227




**Figure 4.** Colorimetric quantification of LAMP reactions. (**A)** Illuminated lightbox with automated image acquisition using Raspberry Pi. 1) Raspberry Pi unit; 2) white LED strip; 3) camera unit; 4) test tube rack. **(B)** LAMP reactions using WHotLAMP with ZI-1 primers on saliva samples from different negative nasal-swab qPCR SARS-CoV-2 individuals (top white box) and SARS-CoV-2 positive (nasal swab) samples (bottom white box). **(C)** Processed image showing conversion of colorimetric LAMP results to hues. **(D)** Hue distribution of WHotLAMP saliva results from negative (-) and positive (+) nasal-swab SARS-CoV-2 qPCR donor samples.




**Figure 5.** Sensitivity and specificity of WHotLAMP. **(A and B)** Sensitivity and **(C and D)** specificity of WHotLAMP using **(A and C)** ZI-1 or **(B and D)** CUFC1 primers with qPCR SARS-CoV-2 positive saliva. Yellow circles denote positive (+) LAMP reactions and magenta circles denote negative (-) LAMP reactions.

## Concluding remarks

We describe WHotLAMP, a simple, inexpensive molecular test (~$3.00 for consumables per reaction at retail prices) that does not require specialized laboratory equipment, to detect SARS-CoV-2 virus in saliva. We show that WHotLAMP can detect low levels of SARS-CoV-2 virus in saliva in 30 minutes. Its low false-positive rate allows for deployment under conditions of low prevalence, where a high test specificity is particularly important to achieve high positive predictive values. The current assay design is already applicable to test at POC settings. Moreover, its single-tube format that requires no centrifugation, is conducive to scaling to 96-well formats, but can also be adapted for home use for frequent self-administered monitoring. While here we focused on a test for SARS-CoV-2, this technology could be used to detect other pathogens that are present in saliva by substituting primers (Bonney et al., 2020), making WHotLAMP a broadly useful diagnostic assay.

252 **Methods**

253 **Saliva RNA spike-in assay**

254 For saliva RNA spike-in tests, a 1.7 mL tube with 100 µL of saliva was combined with 100 µL lysis buffer
255 (0.8 M guanidine hydrochloride (G3272, Sigma), 2% Tween-20 (BP337, Fisher Biotech)), mixed, and
256 incubated at room temperature for 5 min. Approximately $1x10^5$ copies of SARS-CoV-2 RNA
257 (MT007544.1, TWIST Bioscience) were added to the saliva lysate and mixed. A 2x3 mm piece of
258 Whatman No. 1 filter paper (Cat. 1001-929, GE Healthcare) was added to the lysate and incubated at
259 room temperature for 1 min. The lysate was removed and the filter paper was washed twice. For each
260 wash, 1 mL of wash buffer (1 mM Tris-Cl pH 8.0, 0.1 mM EDTA pH 8.0, 0.1% Tween-20) was added,
261 inverted 20x, incubated for 1 minute at room temperature, and then removed. The filter paper was then
262 transferred to a PCR tube containing 40 µL of 1x LAMP reaction mixture (see below).

263 For saliva encapsulated SARS-CoV-2 RNA spike-in tests, the extraction was performed as described for
264 the RNA spike-in assay, except that encapsulated RNA controls (either AccuPlex SARS-CoV-2 or human
265 RNaseP, 0505-0168, LGC Sera Care) were added to the saliva lysate mixture instead of naked RNA. For
266 the no extraction control, encapsulated SARS-CoV-2 RNA control was added directly to saliva without
267 treatment with lysis buffer.

268

269 **WHotLAMP assay**

270 For WHotLAMP assays, a 1.7 mL tube with a piece of Whatman No.1 filter paper (approximately 6 $mm^2$
271 surface area) affixed at the bottom using Kwik-Sil™ silicone (see below) was used to carry out the entire
272 assay. For each sample, 100 µL of saliva was loaded into the tube, followed by 50 µL of RNAlater (R0901,
273 Sigma) and 25 µL of Proteinase K (10 mg/mL) (PB0451, BioBasic; or 25530-049, Ambion), and mixed. The
274 tube was incubated at 26 $^oC$ for 5 min, then at 95 $^oC$ for 5 min, and then returned to room temperature.
275 The saliva mixture was removed and the filter paper was washed twice. For the first wash, 1 mL of wash
276 buffer (1 mM Tris-Cl pH 8.0, 0.1 mM EDTA pH 8.0, 0.1% Tween-20) was added, inverted 20x, incubated
277 for 1 min at room temperature, and then removed. For the second wash, 1 mL of wash buffer was
278 added and the tube was incubated for 1 min at room temperature. The wash buffer was then removed,
279 and 50 µL of 1x LAMP reaction mixture was added (see below).

280

281 **Assay to test for cross-reactivity of respiratory pathogens**
282 ZI-1, CUFC1 and N2+E1 LAMP primers were used in 25 µL colorimetric RT-LAMP reactions conducted in
283 PCR tubes. $1x10^5$ DNA copies of SARS-CoV-1 and MERS, or RNA purified from positive SARS-CoV-2 saliva
284 were added. Reactions were carried out at 65 $^oC$ for 45 min. To test whether ZI-1 primers had cross-
285 reactivity with other respiratory pathogens, the WHotLAMP assay was followed, except that the 100 µL
286 of saliva was substituted with 100 µL of respiratory pathogen mixture (20 µL of a respiratory control
287 panel (NATRPP-1, ZeptoMetrix) or SARS-CoV-2 control (NATSARS(COV2)-ERC, ZeptoMetrix) with 80 µL
288 water).

289 **Collection and processing of patient nasal and saliva samples**

290 With informed consent (Columbia University IRB AAAT1974), patients were provided sterile cotton
291 tipped swabs and conical tubes for sample collection. First, patients underwent separate nose and
292 throat swabs for COVID-19 PCR analysis. For nose swabs, patients were instructed to swab 10 circles per
293 nostril at ~1-2 cm from the nasal opening. For throat samples, patients self-swabbed. Swabs were then
294 placed into 500 µL RLT buffer (RNeasy Mini kit, 74106, Qiagen) with 10 µL beta-mercaptoethanol per 1
295 mL RLT buffer. Participants were instructed, if able, to swish and swallow a small amount of water to
296 clean the mouth. Participants were then asked to produce saliva that naturally pools in their mouth (not
297 expectorated) into a 50 mL Falcon sterile tube. All specimens were assayed within 2 hrs or stored at 4 °C
298 for up to 48 hrs for further analysis.

299 For RNA isolation and real-time qPCR analysis, RNA was purified using the RNeasy Mini Kit (Qiagen) with
300 minor modifications to the standard protocol: Both the nose and throat lysates were combined on a
301 single column for RNA isolation. In addition, only 1 RPE buffer spin was performed, followed by an 80%
302 ethanol spin. The membrane was dried at full speed centrifugation for 5 min. RNA was eluted with two
303 separate 20 µL RNase-free water 5 min incubations and 1 min full speed spins. RNA was transcribed into
304 cDNA utilizing the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) with the following
305 thermocycler settings: 25 °C for 10 min, 37 °C for 60 min, 85 °C for 5 min, then 4 °C until used.

306 Real-time qPCR was performed on cDNA according to standard protocols utilizing TaqPath qPCR Master
307 Mix, ThermoScientific Microamp 96-well reaction plates, and the QuantStudio 3 Real Time PCR system.
308 COVID-19 N1 and N2 FAM primers (2019-nCoV_N1-P, FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1;
309 2019-nCoV_N2-P, FAM-ACA ATT TGC CCC CAG CGC TTC AG-BHQ1) were analyzed out to 40 cycles as
310 compared to 18S rRNA VIC loading control. A 20 µL reaction was performed with 10 µL master mix, 1 µL
311 of COVID-19 N1 or N2 primer sequence, 1 µL of 18s rRNA endogenous control, 4 µL nuclease-free water,
312 and 4 µL RNA were added to each well. All assays were run in duplicate. Each plate was run with a
313 COVID-19 positive control (Integrated DNA Technologies, 2019-nCoV_N_Positive Control, #10006625),
314 and water as a negative control. Samples were deemed negative if by qPCR there was no amplification
315 for N1 or N2. The average Ct of the duplicates was used.
316
317 Saliva samples and WHotLAMP assays were handled and processed under BSL-2 containment. To test
318 the sensitivity of WHotLAMP, patient saliva samples and negative control samples were tested under
319 blind conditions. Saliva samples from healthy volunteers used to assess saliva variability were collected
320 without prior food or beverage restrictions. Samples were tested using the WHotLAMP assay with 1.7
321 mL tubes.
322
323 **Purification of RNA from saliva for RAB7A LAMP and LoD qPCR**

324 RNA was purified from saliva samples using RNeasy Mini columns (Qiagen). 250 µL of saliva was mixed
325 with 250 µL of RLT buffer and 500 µL of 70% ethanol. 500 µL of the mixture was loaded onto a column
326 and centrifuged at 14,000g for 30 s. A second 500 µL volume was loaded onto the same column and
327 centrifuged. The column was washed with 500 µL of RPE, centrifuged, transferred to a new tube, and

328 spun to dry. The column was transferred to a fresh tube and eluted in 20 µL of water. Two additional
329 elutions using 20 µL of water were performed, and all eluates were pooled into one tube.

330

331 **cDNA synthesis for saliva LoD analysis**

332 For cDNA synthesis, total RNA purified from saliva was reverse transcribed using random primers and
333 recombinant M-MuLV reverse transcriptase (E6300S, NEB) according to manufacturer's instructions.
334 Briefly, 50 ng of total RNA was mixed with random primers and denatured for 5 min at 70 °C, spun
335 briefly, and placed on ice. M-MuLV reaction mix and M-MuLV enzyme were added to the mixture and
336 incubated at 25 °C for 5 min, then incubated at 42 °C for 1 hr and heat inactivated at 80 °C for 5 min. The
337 cDNA was then stored at -20 °C until further use.

338

339 **qPCR for saliva LoD analysis**

340 cDNA from SARS-CoV-2 positive saliva and positive control SARS-CoV-2 N gene DNA (2019-nCoV N
341 positive control, IDT Cat. 10006625), were diluted in triplicate. qPCR was performed using CDC N1 and
342 N2 gene primers, their respective fluorescent probes (2019-nCoV_N1 Probe: FAM-ACC CCG CAT TAC GTT
343 TGG TGG ACC-BHQ1 and 2019-nCoV_N2-Probe: FAM-ACA ATT TGC CCC CAG CGC TTC AG-BHQ1) and
344 Taqman Fast Advanced master mix (ThermoFisher, Cat. 4444551), and a QuantStudio 3 Real-Time PCR
345 system (Applied Biosystems) using recommended CDC 2019 nCoV RT-PCR thermocycling parameters. Ct
346 values falling within the linear amplification range were used to estimate SARS-CoV-2 copy number in
347 the cDNA, and an estimated LoD based on copy number was calculated based on the dilutions.

348

349 **RT-LAMP Primers and Assay**

350 Primers (desalted, Integrated DNA Technologies and Eurofins Genomics) used for LAMP reactions were
351 prepared in water as 10x stocks (16 µM FIP/BIP, 2 µM F3/B3, 4 µM LF/LB) (see Table 1). ZI LAMP primer
352 sets were identified using the NEB Primer Design Tool (https://lamp.neb.com/#!/) and a ~800 bp sliding
353 window across the SARS-CoV-2 genomic sequence (MN908947.3). Primer sets with low primer ΔG values
354 (e.g. <-2.2) were selected for further analysis. One primer set, ZI-1, was selected because it was highly
355 sensitive when tested using positive SARS-CoV-2 saliva. All LAMP reactions consisted of 1x colorimetric
356 RT-LAMP mixture (NEB M1800S), 40 mM guanidine hydrochloride (G3272, Sigma, freshly made) and
357 LAMP primers (1.6 µM FIP/BIP, 0.2 µM F3/B3, 0.4 µM LF/LB). Reactions were carried out at 65°C for 20
358 minutes (for 1.7 mL tubes) in a heat block or 45 minutes (for PCR tubes) in a thermocycler. Tubes were
359 cooled afterwards to enhance color contrast between positive and negative colorimetric LAMP results.
360

361

362

363 **Table 2: Primers used in study**

364

| Primer | Sequence |
|---|---|
| ZI-1-F3 | **5'** GGA TAC AAC TAG CTA CAG AGA A **3'** |
| ZI-1-B3 | CCA CAA GTT ACT TGT ACC ATA C |
| ZI-1-FIP | TTG GTA AAG AAC ATC AGA ACC TGA GGC TGC TTG TTG TCA TCT C |
| ZI-1-BIP | CCA CCA CAA ACC TCT ATC ACC TAA CCC TCA ACT TTA CCA GAT |
| ZI-1-LF | AAG TCA TTG AGA GCC TTT GC |
| ZI-1-LB | GTG GTT TTA GAA AAA TGG CAT TCC C |
| CUFC1-F3 | TGG ATA CAA CTA GCT ACA GAG AAG |
| CUFC1-B3 | AGC CAA AGA CCG TTA AGT GTA |
| CUFC1-FIP | GTG GTG GTT GGT AAA GAA CAT CAG ACT TGT TGT CAT CTC GCA AAG G |
| CUFC1-BIP | CCT CTA TCA CCT CAG CTG TTT TGC TGT ACC ATA CAA CCC TCA ACT T |
| CUFC1-LF | ACC TGA GTT ACT GAA GTC ATT GAG A |
| CUFC1-LB | TGG TTT TAG AAA AAT GGC ATT CCC |
| N2-F3 | ACC AGG AAC TAA TCA GAC AAG |
| N2-B3 | GAC TTG ATC TTT GAA ATT TGG ATCT |
| N2-FIP | TTC CGA AGA ACG CTG AAG CGG AAC TGA TTA CAA ACA TTG GCC |
| N2-BIP | CGC ATT GGC ATG GAA GTC ACA ATT TGA TGG CAC CTG TGT A |
| N2-LF | GGG GGC AAA TTG TGC AAT TTG |
| N2-LB | CTT CGG GAA CGT GGT TGA CC |
| E1-F3 | TGA GTA CGA ACT TAT GTA CTC AT |
| E1-B3 | TTC AGA TTT TTA ACA CGA GAG T |
| E1-FIP | ACC ACG AAA GCA AGA AAA AGA AGT TCG TTT CGG AAG AGA CAG |
| E1-BIP | TTG CTA GTT ACA CTA GCC ATC CTT AGG TTT TAC AAG ACT CAC GT |
| E1-LB | GCG CTT CGA TTG TGT GCG T |
| E1-LF | CGC TAT TAA CTA TTA ACG |
| RAB7A-F3 | ACA GGC CTG GTG CTA CAG |
| RAB7A-B3 | CTG CAG CTT TCT GCC GAG |
| RAB7A-FIP | CAA TCG TCT GGA ACG CCT GCT CCC TAC TTT GAG ACC AGT GC |
| RAB7A-BIP | AAG CAG GAA ACG GAG GTG GAG GCC CGG TCA TTC TTG TCC |
| RAB7A-LF | ACG TTG ATG GCC TCC TTG |
| RAB7A-LB | TGT ACA ACG AAT TTC CTG AAC C |
| 2019-nCoV_N1-F | GAC CCC AAA ATC AGC GAA AT |
| 2019-nCoV_N1-R | TCT GGT TAC TGC CAG TTG AAT CTG |
| 2019-nCoV_N1-P | **FAM-**ACC CCG CAT TAC GTT TGG TGG ACC**-BHQ1** |
| 2019-nCoV_N2-F | TTA CAA ACA TTG GCC GCA AA |
| 2019-nCoV_N2-R | GCG CGA CAT TCC GAA GAA |
| 2019-nCoV_N2-P | **FAM-**ACA ATT TGC CCC CAG CGC TTC AG**-BHQ1** |

365

366 **WHotLAMP LoD assay**

367 SARS-CoV-2 positive saliva was initially heat-inactivated at 65 $^{o}$C for 30 min prior to diluting using
368 negative control saliva. An initial series using 10-fold dilutions was tested using WHotLAMP with ZI-1
369 primers. A second series using 2-fold dilutions was tested and repeated 20 times to estimate the
370 consistency at the LoD. Saliva from the same SARS-CoV-2 positive sample was used to extract RNA for
371 RT-qPCR analysis.
372
373 **Adhesive and material handling and testing**

374 Adhesives that could be used to affix Whatman No. 1 filter paper to the bottom of a tube were tested to
375 determine if they were compatible with the LAMP colorimetric assay. A small quantity of liquid
376 adhesives (~2 µL) was spotted at the bottom of a tube and allowed to cure for at least 24 hrs. For solid
377 materials, ~1-2 $mm^2$ pieces were used. Tubes containing different adhesives were incubating in 1x LAMP
378 reaction mixture at 65 $^{o}$C for 20 min (for 1.7 mL tubes) or 45 min (for 0.2 mL PCR tubes). Materials tested
379 were, silicones (Kwik-Sil™ silicone elastomer [World Precision Instruments], aquarium silicone [Aqueon],
380 neutral cure silicone [Dow Corning 737]), liquid glues (Gorilla glue [original, polyurethane], Crazy Glue
381 [Loctite]), glue gun sticks (polyamide [Power Adhesives TEC Bond 7718], acrylic [Infinity Bond], Hot Melt
382 Mini Glue Sticks [Allary]), rubber cement (paper cement [Best-Test]), double-sided tape (Permanent
383 [Scotch, 3M]), plastic strip, (cut from a 175 micron polyester sheet [Grafix Plastics]). To prepare large
384 numbers of 1.7 mL tubes with Whatman No. 1 filter paper glued with Kwik-Sil™, a small aliquot of
385 component A and component B were mixed together and placed on ice to slow the polymerization
386 process. Tear-shaped Whatman filter paper pieces were prepared using a hole-punch. The tapered end
387 of the paper was dipped slightly in Kwik-Sil™ and placed, taper side facing up, at the bottom of the 1.7
388 mL tube using fine-tipped forceps, and air dried for at least 24 hrs.
389
390 **Raspberry Pi lightbox**

391 To quantify colorimetric ranges under uniform conditions we embedded an enclosed white box with: 1)
392 a Raspberry Pi 3 (model B+), 2) camera unit (camera v2.1), and 3) white LED lights (DC12V LED strip). The
393 raspistill command line tool was run to capture still images (raspistill --raw -o png). A color chart (Digital
394 Kolor Kard) inside the box was used as reference to calibrate the white balance of images. Images were
395 then used to extract hues to interpret WHotLAMP positive and negative colorimetric results.

396 **Image processing**

397 We developed a proof-of-concept image analysis pipeline that identified sample results. Images of an
398 array of samples were acquired and thresholded based on color saturation to identify regions of interest
399 (ROIs) corresponding to samples. Areas of high or low brightness as well as areas near the image border
400 were excluded from potential ROIs. We found that this method successfully identified correct ROIs and
401 that the average hue within each ROI formed a bimodal distribution that could be used to successfully
402 categorize samples into positives and negatives

403

404 **Supplementary information**

405 Supplementary Material 1: Python code for LAMP colorimetric result analysis
406
407 Supplementary Material 2: WHotLAMP Protocol
408
409
410 **Author contributions**
411
412 Conceptualization: DN, AB, MV, AP, TT, DP
413 Methodology: DN, AB, MV, AP, HS, EC, SK, BN, FF
414 Validation: DN, MV, AP, UT
415 Formal analysis: DN, AB, MK, ALK
416 Funding: AB, PA
417 Investigation: DN, MV, AP, UT, MG, KS, JD'A, HS, EC, SK, IR-V, BN, FF
418 Resources: MG, KS, JD'A, AE, TT
419 Software: AB, ALK
420 Supervision: DN, AB, JD'A
421 Visualization: DN, AB
422 Writing – original draft: DN, AB, MG, ALK
423 Writing – review & editing: DN, AB, MV, AP, MG, JD'A, ALK, PA
424 Data Curation: AB, MG
425
426 **Acknowledgements**
427 Natalie Steineman, Marjorie Xie, and Aniruddah Das provided organizational support. The Zuckerman
428 Institute Scientific Platforms provided resources. We thank Rui Costa and the Zuckerman Institute for
429 unwavering support.
430
431 **Funding**
432
433 This study was funded by *Friends of the Zuckerman Institute and Columbia University* and NIH grant
434 GM112758 to PA. AB is a Searle Scholar, Klingenstein-Simons Neuroscience Fellow and a Sloan
435 Neuroscience Fellow.
436
437 **Conflicts of interest**
438 Patent application 63/088,694 related to this technology was filed by Columbia University, to facilitate
439 that this technology be made widely available. AB became a member of the advisory board of Rapid
440 Diagnostic Systems Limited for which he received options, after the conclusion of experiments and data
441 analyses described here.

442

443 **References**


444 Baro, B., Rodo, P., Ouchi, D., Bordoy, A. E., Saya Amaro, E. N., Salsench, S. V., Molinos, S., Alemany, A.,
445 Ubals, M., Corbacho-Monné, M., Millat-Martinez, P., Marks, M., Clotet, B., Prat, N., Estrada, O.,
446 Vilar, M., Ara, J., Vall-Mayans, M., G-Beiras, C., … Mitjà, O. (2021). Performance characteristics of
447 five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a
448 head-to-head benchmark comparison. *The Journal of Infection*, *82*(6), 269–275.

449 Batéjat, C., Grassin, Q., Manuguerra, J.-C., & Leclercq, I. (2021). Heat inactivation of the severe acute
450 respiratory syndrome coronavirus 2. In *Journal of Biosafety and Biosecurity* (Vol. 3, Issue 1, pp. 1–
451 3). https://doi.org/10.1016/j.jobb.2020.12.001

452 Ben-Assa, N., Naddaf, R., Gefen, T., Capucha, T., Hajjo, H., Mandelbaum, N., Elbaum, L., Rogov, P., King,
453 D. A., Kaplan, S., Rotem, A., Chowers, M., Szwarcwort-Cohen, M., Paul, M., & Geva-Zatorsky, N.
454 (2020). Direct on-the-spot detection of SARS-CoV-2 in patients. *Experimental Biology and Medicine* ,
455 *245*(14), 1187–1193.

456 Bonney, L. C., Watson, R. J., Slack, G. S., Bosworth, A., Wand, N. I. V., & Hewson, R. (2020). A flexible
457 format LAMP assay for rapid detection of Ebola virus. *PLoS Neglected Tropical Diseases*, *14*(7),
458 e0008496.

459 Butler, D. J., Mozsary, C., Meydan, C., Danko, D., Foox, J., Rosiene, J., Shaiber, A., Afshinnekoo, E.,
460 MacKay, M., Sedlazeck, F. J., Ivanov, N. A., Sierra, M., Pohle, D., Zietz, M., Gisladottir, U., Ramlall, V.,
461 Westover, C. D., Ryon, K., Young, B., … Mason, C. E. (2020). Shotgun Transcriptome and Isothermal
462 Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug
463 Interactions. *bioRxiv : The Preprint Server for Biology*. https://doi.org/10.1101/2020.04.20.048066

464 Casey, M., Griffin, J., McAloon, C. G., Byrne, A. W., Madden, J. M., Mc Evoy, D., Collins, Á. B., Hunt, K.,
465 Barber, A., Butler, F., Lane, E. A., O'Brien, K., Wall, P., Walsh, K. A., & More, S. J. (2020). Pre-
466 symptomatic transmission of SARS-CoV-2 infection: a secondary analysis using published data. In

467 *bioRxiv*. medRxiv. https://doi.org/10.1101/2020.05.08.20094870

468 Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J., & Ho, A. (2021). SARS-CoV-2, SARS-CoV, and
469 MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review
470 and meta-analysis. *The Lancet. Microbe*, *2*(1), e13–e22.

471 Cheng, P. K. C., Wong, D. A., Tong, L. K. L., Ip, S.-M., Lo, A. C. T., Lau, C.-S., Yeung, E. Y. H., & Lim, W. W. L.
472 (2004). Viral shedding patterns of coronavirus in patients with probable severe acute respiratory
473 syndrome. *The Lancet*, *363*(9422), 1699–1700.

474 Choi, J. E., Lyons, K. M., Kieser, J. A., & Waddell, N. J. (2017). Diurnal variation of intraoral pH and
475 temperature. *BDJ Open*, *3*, 17015.

476 Corman, V. M., Haage, V. C., Bleicker, T., Schmidt, M. L., Mühlemann, B., Zuchowski, M., Jo, W. K.,
477 Tscheak, P., Möncke-Buchner, E., Müller, M. A., Krumbholz, A., Drexler, J. F., & Drosten, C. (2021).
478 Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre
479 laboratory evaluation study. *The Lancet. Microbe*. https://doi.org/10.1016/S2666-5247(21)00056-2

480 Dekker, R. J., Ensink, W. A., van Leeuwen, S., Rauwerda, H., & Breit, T. M. (2020). Overhauling a faulty
481 control in the CDC-recommended SARS-CoV-2 RT-PCR test. In *bioRxiv* (p. 2020.06.12.147819).
482 https://doi.org/10.1101/2020.06.12.147819

483 Eisenberg, E., & Levanon, E. Y. (2013). Human housekeeping genes, revisited. *Trends in Genetics: TIG*,
484 *29*(10), 569–574.

485 Johansson, M. A., Quandelacy, T. M., Kada, S., Prasad, P. V., Steele, M., Brooks, J. T., Slayton, R. B.,
486 Biggerstaff, M., & Butler, J. C. (2021). SARS-CoV-2 Transmission From People Without COVID-19
487 Symptoms. *JAMA Network Open*, *4*(1), e2035057.

488 Joung, J., Ladha, A., Saito, M., Kim, N.-G., Woolley, A. E., Segel, M., Barretto, R. P. J., Ranu, A., Macrae, R.
489 K., Faure, G., Ioannidi, E. I., Krajeski, R. N., Bruneau, R., Huang, M.-L. W., Yu, X. G., Li, J. Z., Walker, B.
490 D., Hung, D. T., Greninger, A. L., … Zhang, F. (2020). Detection of SARS-CoV-2 with SHERLOCK One-

491 Pot Testing. *The New England Journal of Medicine*, *383*(15), 1492–1494.

492 Larremore, D. B., Wilder, B., Lester, E., Shehata, S., Burke, J. M., Hay, J. A., Milind, T., Mina, M. J., &
493 Parker, R. (2020). Test sensitivity is secondary to frequency and turnaround time for COVID-19
494 surveillance. *medRxiv : The Preprint Server for Health Sciences*.
495 https://doi.org/10.1101/2020.06.22.20136309

496 La Scola, B., Le Bideau, M., Andreani, J., Hoang, V. T., Grimaldier, C., Colson, P., Gautret, P., & Raoult, D.
497 (2020). Viral RNA load as determined by cell culture as a management tool for discharge of SARS-
498 CoV-2 patients from infectious disease wards. *European Journal of Clinical Microbiology &*
499 *Infectious Diseases: Official Publication of the European Society of Clinical Microbiology*, *39*(6),
500 1059–1061.

501 Liu, C., Geva, E., Mauk, M., Qiu, X., Abrams, W. R., Malamud, D., Curtis, K., Owen, S. M., & Bau, H. H.
502 (2011). An isothermal amplification reactor with an integrated isolation membrane for point-of-
503 care detection of infectious diseases. *The Analyst*, *136*(10), 2069–2076.

504 Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K.,
505 Barnabas, S. L., Bhorat, Q. E., Briner, C., Kwatra, G., Ahmed, K., Aley, P., Bhikha, S., Bhiman, J. N.,
506 Bhorat, A. E., du Plessis, J., Esmail, A., … NGS-SA Group and the Wits-VIDA COVID Group. (2021).
507 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *The New England*
508 *Journal of Medicine*, *384*(20), 1885–1898.

509 Mak, G. C., Cheng, P. K., Lau, S. S., Wong, K. K., Lau, C. S., Lam, E. T., Chan, R. C., & Tsang, D. N. (2020).
510 Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *Journal of Clinical Virology: The*
511 *Official Publication of the Pan American Society for Clinical Virology*, *129*, 104500.

512 Marc, A., Kerioui, M., Blanquart, F., Bertrand, J., Mitjà, O., Corbacho-Monné, M., Marks, M., & Guedj, J.
513 (2021). *Quantifying the relationship between SARS-CoV-2 viral load and infectiousness*. medRxiv.
514 https://doi.org/10.1101/2021.05.07.21256341

515 Marks, M., Millat-Martinez, P., Ouchi, D., Roberts, C. H., Alemany, A., Corbacho-Monné, M., Ubals, M.,
516 Tobias, A., Tebé, C., Ballana, E., Bassat, Q., Baro, B., Vall-Mayans, M., G-Beiras, C., Prat, N., Ara, J.,
517 Clotet, B., & Mitjà, O. (2021). Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort
518 study. *The Lancet Infectious Diseases*, *21*(5), 629–636.
519 Mina, M. J., Peto, T. E., García-Fiñana, M., Semple, M. G., & Buchan, I. E. (2021). Clarifying the evidence
520 on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. *The Lancet*, *397*(10283),
521 1425–1427.
522 Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R.,
523 Türeci, Ö., Dormitzer, P. R., & Şahin, U. (2021). Neutralization of SARS-CoV-2 lineage B.1.1.7
524 pseudovirus by BNT162b2 vaccine–elicited human sera. *Science*, *371*(6534), 1152–1153.
525 Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T., Watanabe, K., Amino, N., & Hase, T. (2000).
526 Loop-mediated isothermal amplification of DNA. *Nucleic Acids Research*, *28*(12), E63.
527 Paltiel, A. D., David Paltiel, A., Zheng, A., & Walensky, R. P. (2020). Assessment of SARS-CoV-2 Screening
528 Strategies to Permit the Safe Reopening of College Campuses in the United States. In *JAMA*
529 *Network Open* (Vol. 3, Issue 7, p. e2016818).
530 https://doi.org/10.1001/jamanetworkopen.2020.16818
531 Petersen, E., Koopmans, M., Go, U., Hamer, D. H., Petrosillo, N., Castelli, F., Storgaard, M., Al Khalili, S., &
532 Simonsen, L. (2020). Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. *The Lancet*
533 *Infectious Diseases*, *20*(9), e238–e244.
534 Pondaven-Letourmy, S., Alvin, F., Boumghit, Y., & Simon, F. (2020). How to perform a nasopharyngeal
535 swab in adults and children in the COVID-19 era. *European Annals of Otorhinolaryngology, Head*
536 *and Neck Diseases*, *137*(4), 325–327.
537 Rabe, B. A., & Cepko, C. (2020). SARS-CoV-2 detection using isothermal amplification and a rapid,
538 inexpensive protocol for sample inactivation and purification. *Proceedings of the National Academy*

539 *of Sciences of the United States of America*, *117*(39), 24450–24458.

540 Regev-Yochay, G., Kriger, O., Beni, S., Rubin, C., Mina, M. J., Mechnik, B., Hason, S., Biber, E., Nadaf, B.,
541 Kreiss, Y., & Others. (2021). Real World Performance of SARS-CoV-2 Antigen Rapid Diagnostic Tests
542 in Various Clinical Settings. *medRxiv*.
543 https://www.medrxiv.org/content/10.1101/2021.03.02.21252400v1.abstract

544 Savela, E. S., Winnett, A., Romano, A. E., Porter, M. K., Shelby, N., Akana, R., Ji, J., Cooper, M. M.,
545 Schlenker, N. W., Reyes, J. A., Carter, A. M., Barlow, J. T., Tognazzini, C., Feaster, M., Goh, Y.-Y., &
546 Ismagilov, R. F. (2021). SARS-CoV-2 is detectable using sensitive RNA saliva testing days before viral
547 load reaches detection range of low-sensitivity nasal swab tests. *medRxiv : The Preprint Server for*
548 *Health Sciences*. https://doi.org/10.1101/2021.04.02.21254771

549 Scohy, A., Anantharajah, A., Bodéus, M., Kabamba-Mukadi, B., Verroken, A., & Rodriguez-Villalobos, H.
550 (2020). Low performance of rapid antigen detection test as frontline testing for COVID-19
551 diagnosis. *Journal of Clinical Virology: The Official Publication of the Pan American Society for*
552 *Clinical Virology*, *129*, 104455.

553 Singanayagam, A., Patel, M., Charlett, A., Lopez Bernal, J., Saliba, V., Ellis, J., Ladhani, S., Zambon, M., &
554 Gopal, R. (2020). Duration of infectiousness and correlation with RT-PCR cycle threshold values in
555 cases of COVID-19, England, January to May 2020. *Euro Surveillance: Bulletin Europeen Sur Les*
556 *Maladies Transmissibles = European Communicable Disease Bulletin*, *25*(32).
557 https://doi.org/10.2807/1560-7917.ES.2020.25.32.2001483

558 Stuart, R. M., Abeysuriya, R. G., Kerr, C. C., Mistry, D., Klein, D. J., Gray, R. T., Hellard, M., & Scott, N.
559 (2021). Role of masks, testing and contact tracing in preventing COVID-19 resurgences: a case study
560 from New South Wales, Australia. *BMJ Open*, *11*(4), e045941.

561 Teo, A. K. J., Choudhury, Y., Tan, I. B., Cher, C. Y., Chew, S. H., Wan, Z. Y., Cheng, L. T. E., Oon, L. L. E., Tan,
562 M. H., Chan, K. S., & Hsu, L. Y. (2021). Saliva is more sensitive than nasopharyngeal or nasal swabs

563 for diagnosis of asymptomatic and mild COVID-19 infection. *Scientific Reports*, *11*(1), 3134.

564 US Food and Drug Administration. (2020a, August 11). *EUA FDA Letter to LumiraDx UK Ltd – LumiraDx*
565 *SARS-CoV-2 RNA STAR*. https://www.fda.gov/media/141054/download

566 US Food and Drug Administration. (2020b, November 13). *EUA FDA letter to Infinity BiologiX LLC –*
567 *Infinity BiologiX TaqPath SARS-CoV-2 Assay*. https://www.fda.gov/media/137773/download

568 US Food and Drug Administration. (2020c, November 17). *EUA FDA Letter to Lucira Health, Inc. – Lucira*
569 *COVID-19 All-In-One Test Kit*. https://www.fda.gov/media/143810/download

570 US Food and Drug Administration. (2020d, December 1). *EUA FDA letter to Dr. Robert R. Redfield, CDC*
571 *2019-Novel Coronavirus (2019-nCoV) Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panel*.
572 https://www.fda.gov/media/134919/download

573 US Food and Drug Administration. (2021, April 1). *EUA FDA letter to Quidel Corporation – Sofia SARS*
574 *Antigen FIA*. https://www.fda.gov/media/137886/download

575 Walsh, K. A., Jordan, K., Clyne, B., Rohde, D., Drummond, L., Byrne, P., Ahern, S., Carty, P. G., O'Brien, K.
576 K., O'Murchu, E., O'Neill, M., Smith, S. M., Ryan, M., & Harrington, P. (2020). SARS-CoV-2 detection,
577 viral load and infectivity over the course of an infection. *The Journal of Infection*, *81*(3), 357–371.

578 Wang, C., Wang, Z., Wang, G., Lau, J. Y.-N., Zhang, K., & Li, W. (2021). COVID-19 in early 2021: current
579 status and looking forward. *Signal Transduction and Targeted Therapy*, *6*(1), 114.

580 Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla,
581 M., Gaebler, C., Lieberman, J. A., Oliveira, T. Y., Yang, Z., Abernathy, M. E., Huey-Tubman, K. E.,
582 Hurley, A., Turroja, M., West, K. A., Gordon, K., Millard, K. G., … Nussenzweig, M. C. (2021). mRNA
583 vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*, *592*(7855), 616–622.

584 Wei, S., Kohl, E., Djandji, A., Morgan, S., Whittier, S., Mansukhani, M., Hod, E., D'Alton, M., Suh, Y., &
585 Williams, Z. (2021). Direct diagnostic testing of SARS-CoV-2 without the need for prior RNA
586 extraction. *Scientific Reports*, *11*(1), 2402.

587 Wouters, O. J., Shadlen, K. C., Salcher-Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., & Jit,
588 M. (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability,
589 allocation, and deployment. *The Lancet*, *397*(10278), 1023–1034.
590 Wyllie, A. L., Fournier, J., Casanovas-Massana, A., Campbell, M., Tokuyama, M., Vijayakumar, P., Warren,
591 J. L., Geng, B., Muenker, M. C., Moore, A. J., Vogels, C. B. F., Petrone, M. E., Ott, I. M., Lu, P.,
592 Venkataraman, A., Lu-Culligan, A., Klein, J., Earnest, R., Simonov, M., … Ko, A. I. (2020). Saliva or
593 Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *The New England Journal of*
594 *Medicine*, *383*(13), 1283–1286.
595 Yamayoshi, S., Sakai-Tagawa, Y., Koga, M., Akasaka, O., Nakachi, I., Koh, H., Maeda, K., Adachi, E., Saito,
596 M., Nagai, H., Ikeuchi, K., Ogura, T., Baba, R., Fujita, K., Fukui, T., Ito, F., Hattori, S.-I., Yamamoto, K.,
597 Nakamoto, T., … Kawaoka, Y. (2020). Comparison of Rapid Antigen Tests for COVID-19. *Viruses*,
598 *12*(12). https://doi.org/10.3390/v12121420
599 Yang, Q., Meyerson, N. R., Clark, S. K., Paige, C. L., Fattor, W. T., Gilchrist, A. R., Barbachano-Guerrero, A.,
600 Healy, B. G., Worden-Sapper, E. R., Wu, S. S., Muhlrad, D., Decker, C. J., Saldi, T. K., Lasda, E.,
601 Gonzales, P. K., Fink, M. R., Tat, K. L., Hager, C. R., Davis, J. C., … Sawyer, S. L. (n.d.). *Saliva TwoStep*
602 *for rapid detection of asymptomatic SARS-CoV-2 carriers*.
603 https://doi.org/10.1101/2020.07.16.20150250
604 Zhang, Y., Odiwuor, N., Xiong, J., Sun, L., Nyaruaba, R. O., Wei, H., & Tanner, N. A. (2020). Rapid
605 molecular detection of SARS-CoV-2 (COVID-19) virus RNA using colorimetric LAMP. In *bioRxiv*.
606 medRxiv. https://doi.org/10.1101/2020.02.26.20028373
607 Zou, Y., Mason, M. G., Wang, Y., Wee, E., Turni, C., Blackall, P. J., Trau, M., & Botella, J. R. (2017). Nucleic
608 acid purification from plants, animals and microbes in under 30 seconds. *PLoS Biology*, *15*(11),
609 e2003916.

610